ASX asthma stocks: Global Health becomes the latest contender

Health software stock Global Health (ASX:GLH) has joined the club of ASX asthma stocks.

The company has nearly doubled in 2020 in conjunction with widespread adoption of telehealth solutions, including its own, Lifecard.

Lifecard is an online facility allowing patients to provide relevant health information directly to their health provider.

Today, Global Health announced a partnership with Asthma Australia, the peak consumer body for asthma patients in Australia.

Asthma Australia wants to halve avoidable asthma hospitalisations by 2030 and will believe Lifecard – a platform that can help asthma patients manage their health and wellbeing – can assist with this.

Lifecard will also be integrated with wearables and remote monitoring devices.

Potential to help 3 million

Asthma Australia estimates almost 3 million Australians live with asthma and this costs the community $28 billion annually.

CEO Michele Goldman said Lifecard could help solve one of the biggest problems asthma patients face.

“People with asthma will often see more than one health professional over the course of time, even multiple visits to different emergency departments,” she said.

“We often hear that people with asthma get rather exhausted retelling their health history, which can be complex and traumatic, and that doctors appreciate the opportunity to assess a health record.”

Global Health boss Matthew Cherian echoed these words saying he was looking forward to what his company could achieve as part of the deal.

“We’re very pleased with the arrangement we have with Asthma [Australia] so we can see if we can help people living with asthma to be more empowered to manage their condition better,” he told Stockhead.

Investors appeared excited too, with the company one of the biggest gainers this morning, surging 50 per cent.

Global Health (ASX:GLH) share price chart

What other ASX asthma stocks are there?

A number of other ASX stocks are in the asthma space, including companies with telehealth solutions.

ResApp (ASX:RAP), Respiri (ASX:RSH) and Adherium (ASX:ADR) all have apps that can monitor and manage asthma treatment.

Medical Developments International (ASX:MVP) sells physical products which optimise asthma treatment including spacers, masks, peak flow meters and portable nebulisers.

A handful of other stocks are in the lung imaging field, whose clientele includes (but is not limited to) asthma patients.

Companies in this space include recently listed 4D Medical (ASX:4DX) as well as Uscom (ASX:UCM) and Cyclopharm (ASX:CYC).

At Stockhead, we tell it like it is. While Respiri is a Stockhead advertiser, it did not sponsor this article.